Deqing and Shanghai, CHINA, July 28, 2015 — Shuwen Biotech Co. Ltd. and Jiangsu Hengrui Medicine Co., Ltd. announced today that they have entered into a collaboration agreement for companion diagnostics development. Under the agreement, Shuwen Biotech will develop companion diagnostic assays and kits for an unidentified anticancer drug candidate Hengrui is developing. Hengrui will also entrust Shuwen to screen patients at Shuwen's diagnostic reference labs using the diagnostic assays for Hengrui's clinical trials. Shuwen will manufacture and market the diagnostic kit upon regulatory approval.
"We are very pleased to have reached this agreement with Shuwen Biotech. Companion diagnostics is an increasingly important component of our drug development. Shuwen is an emerging leader in personalized cancer diagnostics. Shuwen's capabilities in both IVD kits and reference laboratory testing make it an ideal partner in companion diagnostics for our innovative drug development," commented Dr. Lianshan Zhang, President of Global R&D at Hengrui.
"Hengrui Medicine is a leader in targeted therapies for cancer with a full pipeline of innovative drugs in development," stated Jay Z. Zhang, Chairman and CEO of Shuwen Biotech. "This partnership is testimony to the expertise and full capabilities in companion diagnostics we can provide in development, manufacturing, marketing and testing services to our partners and eventually physicians and patients."
About Shuwen Biotech Co., Ltd.
Based in China, Shuwen Biotech is a diagnostic company providing China's doctors and their patients with the most innovative products and services to meet the growing needs for improved prediction, prevention, diagnosis, prognosis, and treatment of diseases, especially in oncology and women's health. The company has capabilities in both IVD kits and laboratory test services. It is engaged in licensing, developing, marketing and distributing innovative diagnostic products and offering diagnostic services. Visit www.shuwenbiotech.com for more information.
About Hengrui Medicine
Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with annual net sales of over US$1.2 billion and annual growth rates of over 20% in the past few years. It is recognized as the top innovative home-grown drug company in China, with over 20 new molecular entities entering clinical trials and dozens more under pre-clinical development. Hengrui's products and R&D span over multiple therapeutic areas, including oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media, and anti-inflammation. Visit http://www.hrs.com.cn for further information.